Nanomix Corporation announced an agreement with Mobility Health, whereby Nanomix and Mobility Health plan to collaborate in the development of an LDT (Lab Developed Test) that can be deployed in a fully mobile lab to evaluate levels of circulating antibodies to COVID-19. Nanomix plans to supply the product elements and Mobility Health plans to complete development and validation of the test, with plans to file for a CLIA Lab Emergency Use Authorization (EUA) with the FDA.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -.--% | -.--% | -.--% |
2023 | Nanomix Corporation Announces Chief Executive Officer Changes | CI |
2023 | Nanomix Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 4.9K | |
-4.70% | 30.03B | |
+36.88% | 9.24B | |
+38.02% | 4.6B | |
-34.42% | 2.57B | |
-9.44% | 1.6B | |
-27.21% | 1.25B | |
-38.46% | 1.06B | |
+7.05% | 972M | |
-41.98% | 792M |
- Stock Market
- Equities
- NNMX Stock
- News Nanomix Corporation
- Nanomix Corporation Announces Agreement with Mobility Health to Co-Develop a Lab Development Test for Evaluating Levels of COVID-19 Circulating Antibodies